Switching Among Multiple Infliximab Biosimilars Does Not Cause Immunogenicity, Study Finds - The Center for Biosimilars

Switching Among Multiple Infliximab Biosimilars Does Not Cause Immunogenicity, Study Finds  The Center for Biosimilars

A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity in patients with ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases